



Republic of the Philippines
DEPARTMENT OF HEALTH
OFFICE OF THE SECRETARY

20 April 2015

JANETTE LORETO- GARIN, MD, MBA-H

Secretary

Department of Health

Dear **Secretary Garin**:

After evaluating the documents submitted by the proponents pertinent to requests for reconsideration on the inclusion of the below listed medicines to the Philippine National Formulary (PNF), the Formulary Executive Council (FEC) respectfully recommends the **disapproval** of the said requests:

Drug	Dosage strength and formulation	FEC recommendation
1. Insulin aspart	100 units/ mL, 3 mL Solution for injection in pre-filled pen	Disapproval Overall, insulin aspart has minimal advantage over regular insulin in terms of efficacy and safety. The cost however is more than 40% over regular human insulin. There is not enough evidence to recommend insulin aspart to be included in the PNF.
2. Rivastigmine	4.6 mg, 9.5 mg and 13.3 mg transdermal patch	Disapproval There was no significant difference in terms of efficacy and safety between rivastigmine patch and capsule. Likewise, the patch is found to be more expensive than the capsule form.

Attached herewith are the evidence summaries considered by the Council.

For your approval, Ma'am.

Very truly yours,

For the Formulary Executive Council

ISIDRO C. SIA

Member

Approved / Disapproved:

JANETTE LORETO- GARIN, MD, MBA-H

Secretary of Health